Dtsch Med Wochenschr 2005; 130(14): 880-882
DOI: 10.1055/s-2005-865102
Prinzip & Perspektive
Gastroenterologie/Onkologie
© Georg Thieme Verlag Stuttgart · New York

Kolonkarzinom: Molekulare Marker

Colon cancer: molecular markersC. N. Arnold1 , H. E. Blum1
  • 1Medizinische Universitätsklinik Freiburg
Further Information

Publication History

eingereicht: 11.10.2004

akzeptiert: 18.2.2005

Publication Date:
31 March 2005 (online)

Glossar

CRC = kolorektales Karzinom

CIN = chromosomale Instabilität

MSI = Mikrosatelliteninstabilität

Literatur

  • 1 Ahlquist D A, Skoletsky J E, Boynton K A. et al . Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.  Gastroenterology. 2000;  119 1219-1227
  • 2 Arnold C N, Blum H E. Molekulare Pathogenese des Kolonkarzinoms: Klinische Relevanz.  Dtsch Med Wochenschr. 2005;  130 809-811
  • 3 Arnold C N, Goel A, Boland C R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.  Int J Cancer. 2003;  106 66-73
  • 4 Barratt P L, Seymour M T, Stenning S P. et al . DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study.  Lancet. 2002;  360 1381-1391
  • 5 Calistri D, Rengucci C, Bocchini R, Saragoni L, Zloi W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool.  Clin Gastro Hepatol. 2003;  1 377-383
  • 6 Carethers J M, Smith E J, Behing C A. et al . Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer.  Gastroenterology. 2004;  126 394-401
  • 7 Dong S M, Traverso G, Johnson C. et al . Detecting colorectal cancer in stool with the use of multiple genetic targets.  J Natl Cancer Inst. 2001;  93 858-865
  • 8 Fallik D, Borrini F, Boige V. et al . Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.  Cancer Res. 2003;  63 5738-5744
  • 9 Müller H M, Oberwalder M, Fiegl H. et al . Methylaion changes in faecal DNA: a marker for colorectal screenng?.  Lancet. 2004;  363 1283-1285
  • 10 Ribic C M, Sargent D J, Moore M J. et al . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.  N Engl J Med. 2003;  349 247-257
  • 11 Sidransky D, Tokino T, Hamilton S R. et al . Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.  Science. 1992;  256 102-105
  • 12 Traverso G, Shuber A, Levin B. et al . Detection of APC mutations in fecal DNA from patients with colorectal tumors.  N Engl J Med. 2002;  346 311-320
  • 13 Traverso G, Shuber A, Olsson L. et al . Detection of proximal colorectal cancers through analysis of faecal DNA.  Lancet. 2002;  359 403-404
  • 14 Watanabe T, Wu T T, Catalano P J. et al . Molecular predictors of survival after adjuvant chemotherapy for colon cancer.  N Engl J Med. 2001;  344 1196-1206
  • 15 Zhou W, Goodman S N, Galizia G. et al . Counting alleles to predict recurrence of early-stage colorectal cancers.  Lancet. 2002;  359 219-225

Dr. med. Christian N. Arnold

Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizin II

Hugstetter Straße 55

79106 Freiburg

Phone: 0761/2703401

Fax: 0761/2703655

Email: arnold@med1.ukl.uni-freiburg.de